Cargando…

Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study

PURPOSE: To investigate real-world clinical outcomes in patients with BRCA-mutated (BRCAm), HER2-negative metastatic breast cancer (mBC) according to BRCA and hormone receptor (HR) status. METHODS: Patients diagnosed with HER2-negative mBC between 01 January 2010 and 31 December 2018 were retrospect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miller, Robert S., Mokiou, Stella, Taylor, Aliki, Sun, Ping, Baria, Katherine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993712/ https://www.ncbi.nlm.nih.gov/pubmed/35194731 http://dx.doi.org/10.1007/s10549-022-06541-3

Ejemplares similares

Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
por: Xu, Binghe, et al.
Publicado: (2022)

HER2-targeted therapy influences CTC status in metastatic breast cancer
por: Deutsch, Thomas M., et al.
Publicado: (2020)

Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens
por: Moy, Beverly, et al.
Publicado: (2021)

Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
por: Chen, Zhaoxu, et al.
Publicado: (2023)

Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer
por: Walter, Vincent, et al.
Publicado: (2020)

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1
por: Rugo, Hope S., et al.
Publicado: (2020)

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
por: Kurozumi, Sasagu, et al.
Publicado: (2016)

The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer
por: Bardia, Aditya, et al.
Publicado: (2022)

Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer
por: Yu, Y. F., et al.
Publicado: (2017)

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
por: Wardley, Andrew, et al.
Publicado: (2021)

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
por: Schuler, Martin, et al.
Publicado: (2012)

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer
por: McIntyre, Kristi, et al.
Publicado: (2014)

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer
por: Modi, Shanu, et al.
Publicado: (2013)

Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
por: Maron, Steven B., et al.
Publicado: (2023)

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2021)

Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA
por: Matsubara, Nobuaki, et al.
Publicado: (2023)

Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958)
por: Thill, Marc, et al.
Publicado: (2022)

High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer
por: Nilsson, Martin P., et al.
Publicado: (2014)

Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
por: Agersborg, Sally, et al.
Publicado: (2018)

Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial
por: Wang, Zijing, et al.
Publicado: (2021)

nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer
por: Hamilton, Erika, et al.
Publicado: (2022)

Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study
por: Vici, Patrizia, et al.
Publicado: (2014)

A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study
por: Lidbrink, Elisabet, et al.
Publicado: (2018)

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study
por: Lynce, F., et al.
Publicado: (2019)

Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer
por: Clemens, Michael R., et al.
Publicado: (2014)

Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer
por: Wilson, Florence R., et al.
Publicado: (2017)

Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study
por: Kuemmel, Sherko, et al.
Publicado: (2021)

EndoPredict(®) in early hormone receptor-positive, HER2-negative breast cancer
por: Almstedt, K., et al.
Publicado: (2020)

Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial
por: Xie, Xiao-Feng, et al.
Publicado: (2022)

Everolimus plus exemestane as first-line therapy in HR(+), HER2(−) advanced breast cancer in BOLERO-2
por: Beck, J. Thaddeus, et al.
Publicado: (2013)

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
por: Lin, Nancy U., et al.
Publicado: (2012)

Pegylated liposomal doxorubicin (Duomeisu(®)) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study
por: Jiang, Hanfang, et al.
Publicado: (2023)

Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital
por: Cunningham, Niamh, et al.
Publicado: (2022)

Exposure–response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters
por: Garg, Amit, et al.
Publicado: (2013)

Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen
por: Yardley, Denise A., et al.
Publicado: (2012)

Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)
por: Watanabe, Kenichi, et al.
Publicado: (2023)

Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
por: Dai, Ming Shen, et al.
Publicado: (2021)

Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)
por: Miles, David, et al.
Publicado: (2013)

Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study
por: Xu, Binghe, et al.
Publicado: (2020)

A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale
por: Isakoff, Steven J, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_upts9gncsfg0on9qsb3o95505q